Lung Cancer
Volume 69, Issue 3 , Pages 307-314 , September 2010

Estimation of an optimal chemotherapy utilisation rate for lung cancer: An evidence-based benchmark for cancer care

  • Susannah Jacob

      Affiliations

    • Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Liverpool Hospital and Faculty of Medicine, University of New South Wales, Sydney, Australia
    • Corresponding Author InformationCorresponding author at: Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Liverpool Hospital, Locked Bag 7103, Liverpool, Sydney, NSW 1871, Australia. Tel.: +61 2 9828 6542; fax: +61 2 9828 6670.
    • ,
  • Elizabeth Hovey

      Affiliations

    • Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia
    • ,
  • Weng Ng

      Affiliations

    • Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Liverpool Hospital and Faculty of Medicine, University of New South Wales, Sydney, Australia
    • ,
  • Shalini Vinod

      Affiliations

    • Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Liverpool Hospital and Faculty of Medicine, University of New South Wales, Sydney, Australia
    • ,
  • Geoff P. Delaney

      Affiliations

    • Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Liverpool Hospital and Faculty of Medicine, University of New South Wales, Sydney, Australia
    • ,
  • Michael B. Barton

      Affiliations

    • Collaboration for Cancer Outcomes Research and Evaluation (CCORE), Liverpool Hospital and Faculty of Medicine, University of New South Wales, Sydney, Australia

Received 15 September 2009 ,Revised 24 November 2009 ,Accepted 29 November 2009.

References 

  1. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol. 2004;22:3860–3867
  2. Spiro SG, Rudd RM, Souhami RL, Brown J, Fairlamb DJ, Gower NH, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax. 2004;59:828–836
  3. Agra Y, Pelayo M, Sacristan M, Sacristan A, Serra C, Bonfill X. Chemotherapy versus best supportive care for extensive small cell lung cancer (Review). Cochrane Database Syst Rev. 2003;(4):[Art.No:CD001990 1-6-2006]
  4. Patel N, Adatia R, Mellemgaard A, Jack R, Moller H. Variation in the use of chemotherapy in lung cancer. Br J Cancer. 2007;96:886–890
  5. Vinod SK, O’Connell DL, Simonella L, Delaney GP, Boyer M, Peters M, et al. Gaps in optimal care for lung cancer. J Thorac Oncol. 2008;3:871–879
  6. Erridge SC, Murray B, Price A, Ironside J, Little F, Mackean M, et al. Improved treatment and survival for lung cancer patients in South-East Scotland. J Thorac Oncol. 2008;3:491–498
  7. American College of Surgeons . National cancer database benchmark reports. 2009;[05.05.09] http://cromwell.facs.org/BMarks/BMPub/Ver9/DxRx/BMPub_DxRx9.cfm
  8. Surveillance Epidemiology and End Results (SEER) Program . SEER*RX antineoplastic drug database. National Cancer Institute, DCCPS, Surveillance Research Program; 2006;[9-1-2006]
  9. National Health and Medical Research Council . Clinical practice guidelines for the prevention, diagnosis and management of lung cancer. [15-3-2006] www.nhmrc.gov.au/publications2004;
  10. National Comprehensive Cancer Network . NCCN Clinical practice guidelines in oncology. Small cell lung cancer. V.2.2009. 2009;[28-10-2009] http://www.nccn.org/professionals/physician_gls/PDF/sclc.pdf
  11. National Cancer Institute . PDQ cancer information summaries: treatment of small cell lung cancer. 2009;[15-9-0009]. http://www.cancer.gov/cancertopics/pdq/treatment/small-cell-lung/healthprofessional/
  12. BC Cancer Agency . Cancer management guidelines for small cell lung cancer. [7-6-2006] www.bccancer.bc.ca2005;
  13. Royal College of Radiologists COIN (Clinical Oncology Information Network) . Guidelines on the non-surgical management of lung cancer. Clin Oncol. 1999;11:S1–S53
  14. Cancer Care Ontario . The role of combination chemotherapy in the initial management of limited stage small-cell lung cancer. Practice Guideline Report # 7-13-1. 2003;[7-6-2006] www.cancercare.on.ca
  15. National Institute for Clinical Excellence and National Collaborating Centre for Acute Care . The diagnosis and treatment of lung cancer. Methods, evidence and guidance. 2005;www.rcseng.ac.uk
  16. American College of Chest Physicians . Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:1S–19S
  17. American Society of Clinical Oncology . Treatment of unresectable non-small cell lung cancer guideline. Update 2003. J Clin Oncol. 2004;22:330–353
  18. National Cancer Institute . PDQ Cancer Information summaries: Treatment of non-small cell lung cancer. 2009;[15-9-2009] http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/healthprofessional/
  19. National Comprehensive Cancer Network . NCCN clinical practice guidelines in oncology. Non-small cell lung cancer. V.2.2009. 2009;[28-10-2009] http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
  20. Cancer Care Ontario . Chemotherapy in stage IV (metastatic) non-small cell lung cancer. Practice guideline report # 7-2. 2002;[14-3-2006] www.cancercare.on.ca
  21. Pisters KMW, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and adjuvant radiation therapy for stages I–IIIA resectable Non-Small-Cell Lung Cancer Guideline. J Clin Oncol. 2007;25:5506–5518
  22. Cancer Care Ontario . Postoperative adjuvant chemotherapy, with or without radiotherapy, in completely resected non-small cell lung cancer: a clinical practice guideline. Evidence-based series # 7-1-2. [7-5-2008] http://www.cancercare.on.ca/pdf/pebc7-1-2s.pdf2006;
  23. BC Cancer Agency . Cancer management guidelines for non-small-cell lung cancer. 2005;[1-5-2006]. www.bccancer.bc.ca
  24. Rowell NP, O’Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2004;[Issue r. Art.No:CD002140.pub2. 2004]
  25. Cancer Care Ontario . Management of unresected stage III non-small cell lung cancer. Practice guideline report # 7-3 (Version 2.2005). 2005;[14-3-2006] www.cancercare.on.ca
  26. National Health and Medical Research Council . Guide to the development, implementation and evaluation of clinical practice guidelines. 1998;[Appendix B, 56]
  27. Delaney G, Jacob S, Featherstone C, Barton MB. The role of radiotherapy in cancer treatment. Estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104:1129–1137
  28. Australian Institute of Health and Welfare (AIHW) . Cancer in Australia; an overview, 2006. 2007;
  29. O’Connell D, Armstrong B, Simonella L, Cancer epidemiology research unit, Cancer Council NSW. Patterns of care in patients with lung cancer. http://www.nswcc.org.au/editorial.asp?pageid=863 Personal Communication.
  30. Birim O, Kappetein P, Goorden T, van Klaveren RJ, Bogers AJ. Proper treatment selection may improve survival in patients with clinical early-stage non-small cell lung cancer. Ann Thorac Surg. 2005;80:1021–1027
  31. El-Sherif A, Gooding WE, Santos R, Pettiford B, Ferson PF, Fernando HC, et al. Outcomes of sublobar resection versus lobectomy for Stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg. 2006;82:408–416
  32. Martini N, Bains MS, Burt ME, Zakowski MF, McCormack P, Rusch VW, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg. 1995;109:120–129
  33. Harpole DH, Herndon JE, Young WG, Wolfe WG, Sabiston DC. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer. 1995;76:787–796
  34. Pasini F, Pelosi G, Valduga F, Durante E, de Manzoni G, Zaninelli M, et al. Late events and clinical prognostic factors in stage I non small cell lung cancer. Lung Cancer. 2002;37:171–177
  35. Park JH, Lee CT, Lee HW, Baek JH, Zo JI, Shim YM. Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer. Eur J Cardiothor Surg. 2005;27:1086–1091
  36. Pairolero PC, Williams DE, Bergstralh EJ, Piehler JM, Bernatz PE, Payne WS. Postsurgical Stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg. 1984;38:331–338
  37. Kagami Y, Nishio M, Narimatsu N, Mjoujin M, Sakurai T, Hareyama M, et al. Radiotherapy for loco-regional recurrent tumours after resection of non-small cell lung cancer. Lung Cancer. 1998;20:31–35
  38. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in small cell lung cancer: a randomised study. J Clin Oncol. 1997;15:893–900
  39. Zhang HX, Yin WB, Zhang LJ, Yang ZY, Zhang ZX, Wang M, et al. Curative radiotherapy of early operable non-small cell lung cancer. Radiother Oncol. 1989;14:89–94
  40. de Rijke JM, Schouten LJ, ten Velde GPM, Wanders SL, Bollen EC, Lalisang RI, et al. Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer. 2004;46:233–245
  41. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys. 1997;38:521–525
  42. Sibley GS, Jamieson TA, Marks LB, Anscher MS, Prosnitz LR. Radiotherapy alone for medically inoperable stage I non-small cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys. 1998;40:149–154
  43. Krol ADG, Aussems P, Noordijk EM, Hermans J, Leer JW. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation?. Int J Radiat Oncol Biol Phys. 1996;34:297–302
  44. Hayakawa K, Mitsuhashi N, Saito Y, Nakayama Y, Furuta M, Sakurai H, et al. Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer. Lung Cancer. 1999;26:137–142
  45. Fry WA, Menck HR, Winchester DP. The national cancer database report on lung cancer. Cancer. 1996;77:1947–1955
  46. Richardson GE, Thursfield VJ, Giles GG. Reported management of lung cancer in Victoria in 1993: comparison with best practice. MJA. 2000;172:321–324
  47. Vinod SK, Delaney GP, Bauman A, Barton MB. Lung cancer patterns of care in south western Sydney, Australia. Thorax. 2003;58:690–694
  48. Mahmud SM, Reilly M, Comber H. Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study. Lung Cancer. 2003;41:57–64
  49. Gregor A, Thomson CS, Brewster DH, Stroner PL, Davidson J, Ferguson RJ, et al. Management and survival on lung cancer in Scotland diagnosed in 1995: results of a national population based study. Thorax. 2001;56:212–217
  50. Pepe C, Hasan B, Winton TL, Seymour L, Graham B, Livingstone RB, et al. Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol. 2007;25:1553–1561
  51. Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol. 2001;19:1064–1070
  52. Langer CJ, Hsu C, Curran WJ. Elderly patients with locally advanced non-small cell lung cancer benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94-10. Proc Am Soc Clin Oncol. 2002;21(299a):[abstr 1193.].
  53. Chen YM, Perng RP, Shih JF, Tsai CM, Whang-Peng J. Chemotherapy for non-small cell lung cancer in elderly patients. Chest. 2005;128:132–139
  54. Janssen-Heijnen ML, Schipper RM, Razenberg PPA, Crommelin MA, Coebergh JW. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 1998;21:105–113
  55. Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope. 2000;110:593–602
  56. de Ruysscher D, Botterweck A, Dirx M, Pijls-Johannesma M, Wanders R, Hochstenbag M, et al. Eligibility for concurrent chemotherapy and radiotherapy for locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol. 2009;20:98–102
  57. Janssen-Heijnen ML, Smulders S, Lemmens VEPP, Smeenk FW, van Geffen HJ, Coebergh JW. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax. 2004;59:602–607
  58. Shepherd FA, Amdemichael E, Evans WK, Chalvardjian P, Hogg-Johnson S, Coates R, et al. Treatment of small-cell lung cancer in the elderly. J Am Geriatr Soc. 1994;42:64–70
  59. Dajczman E, Fu LY, Small D, Wallkove N, Kreisman H. Treatment of small cell lung carcinoma in the elderly. Cancer. 1996;77:2032–2038
  60. Jansen SJT, Otten W, Stiggelbout AM. Review of determinants of patients’ preferences for adjuvant therapy in cancer. J Clin Oncol. 2004;22:3181–3190
  61. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ. 1998;317:771–775
  62. Hirose T, Horichi N, Ohmori T, Kusumoto S, Sugiyama T, Shirai T, et al. Patient preferences in chemotherapy for advanced non-small cell lung cancer. Int Med. 2005;44:107–113

PII: S0169-5002(09)00594-7

doi: 10.1016/j.lungcan.2009.11.017

Lung Cancer
Volume 69, Issue 3 , Pages 307-314 , September 2010

Article Tools

* Image Usage & Resolution